Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs

Highly purified cannabidiol (CBD) has demonstrated efficacy with an acceptable safety profile in patients with Lennox‐Gastaut syndrome or Dravet syndrome in randomized, double‐blind, add‐on, controlled phase 3 trials. It is important to consider the possibility of drug‐drug interactions (DDIs). Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Patsalos, Philip N., Szaflarski, Jerzy P., Gidal, Barry, VanLandingham, Kevan, Critchley, David, Morrison, Gilmour
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Critical Review and Invited Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693203/
https://www.ncbi.nlm.nih.gov/pubmed/32918835
http://dx.doi.org/10.1111/epi.16674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693203/
https://www.ncbi.nlm.nih.gov/pubmed/32918835
http://dx.doi.org/10.1111/epi.16674

Ejemplares similares